Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CURLF NASDAQ:CYTK NASDAQ:KRYS NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$3.64$8.48$0.72▼$5.05$2.54B1.531.24 million shs1.32 million shsCYTKCytokinetics$79.17+0.5%$71.75$31.99▼$80.80$9.80B0.421.78 million shs2.89 million shsKRYSKrystal Biotech$343.43-1.3%$297.62$130.50▼$356.50$10.26B0.53279,902 shs411,621 shsNUVLNuvalent$123.420.0%$106.49$71.13▼$123.62$9.75B1.154.92 million shs2.09 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf0.00%0.00%-63.45%-46.91%+51.67%CYTKCytokinetics+0.50%+10.91%+2.90%+31.91%+144.13%KRYSKrystal Biotech-1.33%+5.75%+14.69%+38.99%+159.27%NUVLNuvalent-0.01%+0.06%+20.86%+28.36%+64.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$3.64$8.48$0.72▼$5.05$2.54B1.531.24 million shs1.32 million shsCYTKCytokinetics$79.17+0.5%$71.75$31.99▼$80.80$9.80B0.421.78 million shs2.89 million shsKRYSKrystal Biotech$343.43-1.3%$297.62$130.50▼$356.50$10.26B0.53279,902 shs411,621 shsNUVLNuvalent$123.420.0%$106.49$71.13▼$123.62$9.75B1.154.92 million shs2.09 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf0.00%0.00%-63.45%-46.91%+51.67%CYTKCytokinetics+0.50%+10.91%+2.90%+31.91%+144.13%KRYSKrystal Biotech-1.33%+5.75%+14.69%+38.99%+159.27%NUVLNuvalent-0.01%+0.06%+20.86%+28.36%+64.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCURLFCuraleaf 3.25BuyN/AN/ACYTKCytokinetics 2.86Moderate Buy$99.3025.43% UpsideKRYSKrystal Biotech 2.83Moderate Buy$340.56-0.84% DownsideNUVLNuvalent 2.20Hold$131.156.26% UpsideCurrent Analyst Ratings BreakdownLatest CURLF, NUVL, KRYS, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026KRYSKrystal Biotech TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$306.00 ➝ $403.006/17/2026CYTKCytokinetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$119.006/17/2026CYTKCytokinetics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.006/16/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)6/16/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$310.00 ➝ $361.006/10/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/10/2026NUVLNuvalent GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$151.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/9/2026NUVLNuvalent Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$140.00 ➝ $124.006/9/2026NUVLNuvalent TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$124.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCURLFCuraleaf$1.27B2.01$0.05 per share66.42$1.11 per share3.28CYTKCytokinetics$88.04M111.89N/AN/A($5.39) per share-14.69KRYSKrystal Biotech$389.13M26.02$7.19 per share47.75$42.06 per share8.17NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCURLFCuraleaf-$231.07M-$0.13N/AN/AN/A-7.76%-8.11%-2.36%N/ACYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4845.9132.65N/A53.92%19.25%17.62%8/3/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)Latest CURLF, NUVL, KRYS, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/5/2026Q1 2026CURLFCuraleaf-$0.24$0.27+$0.51$0.09$316.62 million$324.23 million5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCURLFCuraleafN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCURLFCuraleaf1.051.560.74CYTKCytokineticsN/A4.214.21KRYSKrystal BiotechN/A9.469.06NUVLNuvalentN/A16.1416.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCURLFCuraleaf0.03%CYTKCytokineticsN/AKRYSKrystal Biotech86.29%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipCURLFCuraleafN/ACYTKCytokinetics2.60%KRYSKrystal Biotech13.10%NUVLNuvalent5.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCURLFCuraleaf5,554698.73 millionN/ANot OptionableCYTKCytokinetics250124.43 million121.20 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableCURLF, NUVL, KRYS, and CYTK HeadlinesRecent News About These CompaniesNuvalent (NASDAQ:NUVL) Sees Strong Trading Volume - Time to Buy?June 20 at 4:23 AM | americanbankingnews.comNuvalent, Inc. $NUVL Position Lifted by Perceptive Advisors LLCJune 18, 2026 | marketbeat.comPolar Capital Holdings Plc Boosts Position in Nuvalent, Inc. $NUVLJune 17, 2026 | marketbeat.comNUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSKJune 16, 2026 | globenewswire.comNicholas Investment Partners LP Boosts Holdings in Nuvalent, Inc. $NUVLJune 14, 2026 | marketbeat.comFirst Turn Management LLC Has $37.09 Million Stock Holdings in Nuvalent, Inc. $NUVLJune 14, 2026 | marketbeat.comMarketBeat Week in Review – 06/08 - 06/12 (NUVL)...June 13, 2026 | marketbeat.comRhenman & Partners Asset Management AB Acquires 110,850 Shares of Nuvalent, Inc. $NUVLJune 13, 2026 | marketbeat.comGuggenheim downgrades Nuvalent (NUVL) to a HoldJune 12, 2026 | theglobeandmail.comNuvalent (NUVL) was downgraded to a Hold Rating at TD CowenJune 12, 2026 | theglobeandmail.comTop Medical Stocks To Consider - June 9thJune 12, 2026 | americanbankingnews.comBest Pharmaceutical Stocks To Consider - June 9thJune 12, 2026 | americanbankingnews.comPromising Mid Cap Stocks To Follow Now - June 9thJune 12, 2026 | americanbankingnews.comNuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase InhibitorsJune 11, 2026 | seekingalpha.comPatent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion...June 11, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Downgraded by Truist Financial to HoldJune 11, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Upgraded to Hold at GuggenheimJune 11, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Downgraded by Canaccord Genuity Group to HoldJune 11, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Downgraded by Barclays to HoldJune 11, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Rating Lowered to "Hold" at Robert W. BairdJune 11, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) CEO James Richard Porter Sells 30,000 SharesJune 11, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026CURLF, NUVL, KRYS, and CYTK Company DescriptionsCuraleaf OTCMKTS:CURLF$3.64 0.00 (0.00%) As of 06/4/2026Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.Cytokinetics NASDAQ:CYTK$79.17 +0.39 (+0.50%) Closing price 06/22/2026 04:00 PM EasternExtended Trading$79.50 +0.33 (+0.41%) As of 06/22/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$343.43 -4.63 (-1.33%) Closing price 06/22/2026 04:00 PM EasternExtended Trading$349.00 +5.57 (+1.62%) As of 06/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$123.42 -0.01 (-0.01%) Closing price 06/22/2026 04:00 PM EasternExtended Trading$123.44 +0.02 (+0.02%) As of 06/22/2026 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy CrowdStrike Before the Stock Split? Here's the Case USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
